A Dose-Ranging Safety, Tolerability, and Exploratory Efficacy Study of Adjunctive EQU-001 for Seizures in Adults With Epilepsy
Latest Information Update: 17 May 2023
At a glance
- Drugs EQU-001 (Primary)
- Indications Epilepsy; Seizures
- Focus Adverse reactions
- Sponsors Equilibre Biopharmaceuticals
- 11 May 2023 Planned End Date changed from 15 Oct 2022 to 11 Oct 2023.
- 11 May 2023 Status changed from completed to active, no longer recruiting.
- 30 Jan 2023 According to Equilibre Biopharmaceuticals Media Release, the open-label extension for EQU-201 is ongoing and expected to generate long-term data for EQU-001